Eldec Pharmaceuticals
Chapel Hill, US · Delaware corporation · 1 known investors
Eldec is a biotechnology company developing peptide-based therapeutics targeting SPLUNC1's modulation of Orai1 activity, with lead programs ELD615 and ELD607 for lung diseases such as cystic fibrosis and non-CF bronchiectasis. Its research programs are supported by NHLBI, NIAID, NIDDK, and the North Carolina Biotechnology Center.
BiotechHealthtech
Founders & leadership
RT
Robert TarranCo-founder, President & Chief Scientific Officer
RS
Robert SchotzingerExecutive Officer, Director
SA
Saira AhmadCo-founder
FS
Flori SassanoCo-founder
RJ
Robert J. SchotzingerChairman & Chief Executive Officer
RH
Robert HughesChief Financial Officer
DJ
Dale J. ChristensenChief Development Officer
Investors · 1
Reported raises · per SEC filings
Form D private placements▶$200KraisedFeb 2026 · 1 investors · PharmaceuticalsRule 506(b)
▶$200KraisedFeb 2026 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert TarranExecutive Officer, Director
- Robert SchotzingerExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $200K
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.